The peer-reviewed body of work that anchors endogenic pharmacology in the standard literature of biomedical science.
Endogenic pharmacology rests on a body of peer-reviewed research published across more than four decades in standard biomedical and biochemical journals — not on grey literature, not on consumer wellness claims, and not on speculative theory.
The body of literature spans cellular biochemistry, in-vivo pharmacology, mechanism-of-action studies, clinical observation, and longevity research, with replications across multiple institutional research programs and multiple geographic regions.
Institutional laboratories — most prominently the Saint Petersburg Institute of Bioregulation and Gerontology — produced the foundational body of biochemical, in-vivo, and clinical research that characterizes the privileged short-peptide subclass.
Ukrainian biochemistry institutes contributed extensively to the structural and mechanistic resolution of bioregulator action, including isolation chemistry, peptide synthesis methodology, and pharmacological standardization.
Italian molecular-biology and gerontology research groups contributed independent replication of bioregulator gene-regulatory action, expanded the indication space toward neurodegenerative and ophthalmic targets, and provided cross-cultural peer review of the discipline's empirical claims.
Korean clinical and molecular research extended the bioregulator literature into modern molecular-biology methodology, including chromatin-immunoprecipitation studies, transcriptomic profiling, and contemporary safety/pharmacokinetic characterization.
U.K. academic and clinical research provided independent in-vivo and clinical-observational replication, particularly within longevity-research-program contexts and within the broader peptide-therapeutics literature.
The bioregulator therapeutic class consists of short peptides — di-, tri-, and tetra-peptide sequences — characterized over forty years of pharmaceutical research. Each compound has its own published-literature subsection within this archive, with structural and nomenclature data, native and modified-form distinctions, and peer-reviewed reference lists.
Ala-Glu-Asp-Gly. Pineal and longevity research; telomerase activation literature.
Read →Lys-Glu-Asp. Vascular and endothelial regulation literature.
Read →Gly-His-Lys. Wound healing, collagen, and tissue regeneration literature.
Read →Glu-Asp-Arg. Neurological and cortical gene-expression literature.
Read →Lys-Glu. Immune regulation and thymopoietic literature.
Read →Glu-Trp. Thymic immune regulation literature.
Read →Val-Ala-Gly. Pineal and reproductive regulation literature.
Read →Ala-Glu-Asp. Vascular, renal, and companion-animal CKD literature.
Read →Seven novel acetylated and amidated dual-terminus analogs. Atumnus IP estate.
Read →A working bibliography for the discipline is maintained for access by qualified researchers and clinicians. Inquiries from academic, clinical, or institutional contexts can be directed through the Contact for Researchers pathway.